Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
AbbVie Acquires Celsius Therapeutics
09:26am, Thursday, 27'th Jun 2024
Celsius' CEL383 is a potential first-in-class anti-Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) antibody for the treatment of inflammatory bowel disease (IBD) NORTH CHICAGO, Ill. , June 27
Introducing Allē Payment Plans, Powered by Cherry
08:30am, Thursday, 27'th Jun 2024
Allē Members Enjoy the Aesthetic Treatments They Love Today, and Pay Over-Time with No Hard Credit Checks Participation Comes at No Cost* to Aesthetic Providers for Allergan Aesthetics Treatments and
Can AbbVie Stock Keep Outpacing the S&P 500?
05:30am, Thursday, 27'th Jun 2024
AbbVie's shares have outshined the red-hot S&P 500 over the prior 12 months. Even so, the drugmaker's shares remain in bargain territory.
Nxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone
07:05pm, Wednesday, 26'th Jun 2024
Tokyo, Japan and Cambridge, UK, 27 June 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565), announces that it has reached an important R&D milestone under its multi-target discovery collaboration wit
- EPKINLY is now the first and only bispecific antibody approved in the U.S. to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL)- Bis
AbbVie (ABBV) Parkinson's Candidate Faces 2nd FDA Rejection
10:05am, Wednesday, 26'th Jun 2024
AbbVie (ABBV) issues the second CRL for Parkinson's disease medicine, ABBV-951, based on some observations on inspection of one of its third-party manufacturing facilities.
AbbVie (ABBV) Stock Dips While Market Gains: Key Facts
06:50pm, Tuesday, 25'th Jun 2024
AbbVie (ABBV) reachead $170.75 at the closing of the latest trading day, reflecting a -1.15% change compared to its last close.
US FDA declines to approve AbbVie's Parkinson's disease therapy
08:26am, Tuesday, 25'th Jun 2024
AbbVie said on Tuesday the U.S. Food and Drug Administration has rejected the company's marketing application for its therapy to treat motor fluctuations in adults with advanced Parkinson's disease.
AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)
08:15am, Tuesday, 25'th Jun 2024
U.S. Food and Drug Administration (FDA) issues Complete Response Letter (CRL) for ABBV-951 based on observations from an inspection that did not involve ABBV-951 at one of AbbVie's third-party manufac
3 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income
04:31am, Tuesday, 25'th Jun 2024
AbbVie is one of the world's largest pharmaceutical companies and one of the fastest dividend raisers in its industry. Shares of business development company Ares Capital offer a yield above 9% at rec
Hot Summer Dividends: 3 Sizzling Stocks to Buy for Reliable Income
11:25am, Monday, 24'th Jun 2024
With the stock market near all-time highs, I'm looking forward to the next market crash. Yes, I want the stock market to fall and fall hard.
3 Biotech Stocks to Buy Now: June 2024
02:00pm, Friday, 21'st Jun 2024
Recently, the biotech industry has taken a bit of a slower stance toward growth. With the Covid-19 pandemic in the rearview mirror, the focus of major pharmaceutical developers and biotech companies s
AbbVie Declares Quarterly Dividend
08:00am, Friday, 21'st Jun 2024
NORTH CHICAGO, Ill. , June 21, 2024 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.55 per share.
AbbVie stock price forecast: $200 on the cards?
09:27am, Thursday, 20'th Jun 2024
On June 20, 2024, AbbVie Inc. (NYSE:ABBV) announced that it has received FDA approval for expanding the use of its interleukin-23 (IL-23) inhibitor, Skyrizi, to treat adults with moderate to severe ul
Wall Street Favorites: 3 Retirement Stocks With Strong Buy Ratings for June 2024
09:00am, Thursday, 20'th Jun 2024
As we move into June, I've identified three top retirement stocks that could be excellent long-term investments. While many investors have been focused on the cryptocurrency market, as Bitcoin ( BTC-U
